Four things your body uses them for
Your body uses peptides for almost everything important.
Hunger & Metabolism
Peptides tell your brain when you're full and signal your body to burn or store fat. The drugs behind Ozempic and Wegovy are peptides. They work by mimicking a hormone your gut already makes after eating.
Healing & Recovery
Some peptides accelerate how the body repairs itself: muscle, tendons, skin, and gut lining. This is why athletes and people recovering from injury seek them out.
Hormones & Growth
The pituitary gland releases growth hormone in response to peptide signals. Recreating those signals is how researchers target body composition, sleep quality, and age-related hormone decline.
Immune & Defense
The immune system coordinates its response using peptide signals. Some therapeutic peptides amplify or modulate that response, used internationally for hepatitis, cancer, and immune conditions.
Ozempic is a peptide. So is the compound your neighbor is injecting from a vial with no label. The same science underpins both. The difference is in the testing, oversight, and documentation structures that exist between the lab and the person using it. This site maps that difference accurately.
How to use this site
Not sure where to start?
Follow the order.
Each section of this site was built to answer a specific question a curious person would ask. Start at 01. Every step builds naturally on the one before.
What compounds actually exist?
22 peptides covered in full, from FDA-approved drugs you've already heard of to grey market research chemicals most people don't know how to evaluate. Each entry covers what it is, what the science actually says, and the context that shapes how different people evaluate it.
Browse all compoundsWhat does it do to your body, specifically?
An interactive body map. Pick any compound and watch the systems it targets light up, color-coded by how strong the actual evidence is at each target. Green means strong human trial data. Yellow means early or limited data. Red means the mechanism is proposed but not yet proven in people.
Open the body mapHow does it get from a lab to your door?
Four completely different paths: a licensed pharmacy, a compounding pharmacy, a grey market vendor, and the raw global supply chain behind all three. The regulatory frameworks, testing requirements, and oversight structures are substantially different across each lane. Most people never see them.
See the supply chainWhat do the numbers actually look like?
Visual breakdowns of the regulatory landscape, clinical trial pipelines, and market structure. Designed to be referenced, screenshotted, and shared.
View the dataWhat's happening in the industry right now?
The Signal is the weekly briefing from Daily Peptide. Every Sunday: what the FDA did, which trials read out results, what the industry is watching. One email. Independent. No vendor influence. Free.
Subscribe to The SignalHave a specific question?
Submit it directly to the publication. Questions can be anonymous or public. Public answers are answered editorially and archived on the site. Private questions reach the publication directly.
Ask Daily PeptideWhy this site was built
The middle was empty.
Two types of content dominate the peptide space. Vendor marketing that wants you to buy something. Clinical research papers written for scientists, not people. Neither is written for the person in the middle, curious, skeptical, trying to make sense of what's real and what's hype.
Daily Peptide is the middle done right. Every claim sourced against primary research. Every regulatory status verified. Every piece of coverage independent of every commercial interest in the industry: vendors, pharmacies, telehealth companies, and everyone else.
No affiliate links. No vendor sponsorship. No dosing advice. No hype words. Just the science, the regulatory reality, and the industry context, written for the person who actually wants to understand.
The four categories
Everything on this site falls into one of four lanes.
The lane a compound is in tells you how it was reviewed, how it can be accessed, and what oversight structures apply. That context shapes how the evidence should be read.
An example: what a full breakdown looks like
The most effective weight loss drug ever recorded in a clinical trial. Still not FDA approved.
Retatrutide
Eli Lilly's drug targets three separate hormone receptors at once, telling your brain you're full, improving how your body handles sugar, and actively burning fat at the metabolic level. The Phase 3 trials produced weight loss numbers the medical field had never seen in a study of this kind. The FDA review is on track. The regulatory category the drug lands in is still contested.
28.7%
AVERAGE BODY WEIGHT LOST · 68 WEEKS
71.2 lb
PEAK WEIGHT LOST IN TRIAL
Q4 2026
PROJECTED FDA APPLICATION
The Signal · Every Sunday
Stay current without having to become an expert.
What the FDA did this week. Which trials reported results. What the industry is tracking next. One email, every Sunday. Independent. No vendor influence. Free.
Subscribe to Daily Peptide
Weekly editorial briefing. Evidence-led. Independent.
Watching
What Daily Peptide is tracking right now.
For readers who've made it this far. The active FDA decisions, trial readouts, and industry developments the publication is watching closely.
PCAC · JUL 23–24, 2026
Seven compounds face their first formal Western regulatory review
BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon are scheduled for review by the Pharmacy Compounding Advisory Committee. The outcome determines compounding eligibility at licensed pharmacies, not drug approval. These are two different things.
PIPELINE
Retatrutide: FDA approval application projected Q4 2026
Eli Lilly's triple-agonist, which produced the highest Phase 3 weight loss ever recorded, is on track to file for FDA approval in Q4 2026. If approved 2027–2028, it would become the first triple-agonist in the class.
COMPOUNDING
Semaglutide and tirzepatide removed from compounding list
The FDA proposed on April 30, 2026 to permanently remove semaglutide and tirzepatide from the list of compounds that licensed pharmacies can make. Public comment closed June 29, 2026. Legal challenges are ongoing. The practical impact on patients is still unfolding.
CARDIOVASCULAR
Tirzepatide's major heart outcomes trial still running
A 15,000-person trial is testing whether tirzepatide reduces heart attacks and strokes in people with obesity. Expected to complete October 2027. This is the same milestone semaglutide achieved in 2023, and it would significantly expand tirzepatide's clinical case.
Daily Peptide is an independent peptide research publication. Educational. Not medical advice.